All In Biotech

Drug Trial Radar · NCT04514419

Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel

A Phase III Study to Compare HS627 vs. Pertuzumab on the Efficacy, Safety and Immunogenicity in Combination With Trastuzumab and Docetaxel as Neoadjuvant Therapy in Patients With Early-stage or Locally Advanced HER2 Positive Breast Cancer

Last checked: Nov 19, 2026Latest source record: Nov 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 408 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

408

Planned (sponsor's estimate)

Start

Jun 28, 2020

Primary completion

Sep 11, 2024

Study completion Dec 2025

Sponsor

Sponsor type
Industry
First posted
Aug 17, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The trial included screening period (4 weeks) and treatment period (4 treatment cycles, at least 12 weeks).

Conditions

  • Breast Cancer

Interventions

  • HS627Drug

    Prior to surgery: trastuzumab, HS627, and docetaxel for 4 cycles (1 cycle = 21 days).

  • PertuzumabDrug

    Prior to surgery: trastuzumab, Pertuzumab, and docetaxel for 4 cycles (1 cycle = 21 days).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of participants achieving Pathological Complete Response (pCR) as Assessed by the Independent Review Committee (IRC)Time frame: After surgery (At surgery cycle 4 Days 22-35)(1 cycle = 21 days)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Affiliated Hospital of Qingdao University

    Qingdao, Shandong, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.